Background
The intricate immune network in TME of HCC
Representative immunosuppressive components in TME of HCC
Myeloid-derived suppressor cells (MDSCs)
Tumor-associated macrophages (TAMs)
Tumor associated neutrophils (TANs)
Tumor-infiltrating lymphocytes (TILs)
Regulatory T cell (Treg)
CD8+ cytotoxic T lymphocytes (CTLs)
Innate immune players and stromal components
Natural killer (NK) cells
Kupffer cells (KCs)
Dendritic cells (DCs) and DC-based vaccines
Agents | Descriptions | Trial category | Biological effects or clinical results | References |
---|---|---|---|---|
AFP and interleukin 18 engineered DCs (AFP/IL-18-DCs) | DCs co-transduced with the AFP gene and IL-18 | In vitro studies | • Significantly increase the production of IFN-γ • Promote CD4+ T cells proliferation; elevate CTLs activity against AFP-expressing HCC cells | [97] |
DCs pulsed with NY-ESO-1 | DCs pulsed with the recombinant NY-ESO-1 protein | In vitro studies | • Be more effective in stimulating T cell proliferation compared with immature DCs | [98] |
IL-12 engineered DCs (IL-12-DCs) | Endogenous IL-12-expression by adenoviral gene transfer effectively enhances immunostimulation of DC | Translational trials with murine models | • Induce a sufficient Th1 TME allowing the recruitment of Teff to enhance anti-tumor immunity • Improve dendritic cells (DCs)-based immunotherapy of HCC | [99] |
CD40 Ligand-Expressing DCs | Transduction of TAA-pulsed DCs with CD40L-encoding adenovirus (Ad-CD40L) | Translational trials with mice models | • Promote DC immunostimulation with up-regulation of CD80/CD86 and IL-12 expression • Increase tumor infiltration with CD4+, CD8+ T cells and NK cells • Elevate IFN-γ release and CTLs cytotoxicity | [100] |
TEXs pulsed DCs | Tumor cell derived exosomes (TEXs)-pulsed DCs | In vitro and in vivo orthotopic HCC mice models | • Increase numbers of T lymphocytes infiltration, elevate IFN-γ production; decrease IL-10, TGF-β in tumor sites • Elicit a stronger immune response than cell lysates in vitro and in vivo | [95] |
A new form vaccine: DCs-DEXs | Exosomes derived from AFP- expressing DCs | Translational investigation in mouse models | • A cell-free vaccine option for HCC immunotherapy • Decrease Tregs infiltration, IL-10, TGF-β in tumor sites • Reshape the TME in HCC | [96] |
TAAs pulsed DCs vaccine | α-fetoprotein, glypican-3 and MAGE-1 recombinant fusion proteins pulsed DCs | A prospective phase I/II clinical study in 5 HCC patients | • Result: safe and well-tolerated • Over 95% of DCs demonstrated highly expressed MHC class I (HLA-ABC), MHC class II (HLA-DR), and costimulatory molecules (CD86, CD80, and CD40) • Induce Th1 immune responses with highly produced IL-12, IFN-γ • Trigger stronger CTLs responses | [101] |
TAAs pulsed DCs vaccine | α-fetoprotein, glypican-3 and MAGE-1 recombinant fusion proteins pulsed DCs | A prospective phase I/II clinical study in 12 HCC patients | • Result: safe and well-tolerated • 1-, 2-, and 5-year cumulative RFS rates were improved | [102] |
DCs pulsed with tumor cell lysate | Mature autologous DCs pulsed exvivo with HepG2 lysate | A phase II clinical trial with 35 patients with advanced HCC | • Result: safe and well-tolerated • MS: 168 days; 6-month survival rate: 33%; 1-year survival rate 11% • Induce stronger T cell responses and IFN-γ release | [103] |
DCs pulsed with tumor cell lysate | Mature autologous DCs pulsed ex vivo with HepG2 lysate | A clinical trial with 2 groups: Group1: 15 advanced HCC patients received DCs vaccination Group2: control group | • Result: safe and well-tolerated • CD8+ T cells and serum IFN-γ were elevated after DCs injection • Partial radiological response: 13.3%; stable course: 60%; and 26.7% showed progressive disease and died at 4 months post-injection | [104] |
DCs pulsed with AFP | AFP peptides pulsed onto autologous DCs | A phase I/II clinical trial in which HLA-A*0201 patients with AFP-positive HCC, 10 patients received DCs vaccination | • 6 of 10 subjects increased IFN-γ producing AFP-specific T cell responses | [105] |
Representative immune inhibitory factors and modulators
Cytokines/signaling molecules | Category | Description | References |
---|---|---|---|
IL-1β | Pro-inflammatory cytokine | • A favorable factor for prolonged OS of HBV-related HCC patients • TAMs-secreted IL-1β in HCC contributes to HIF-1α stability, IL-1β/HIF-1α induce EMT and metastasis of HCC | |
IL-12 | Pro-inflammatory cytokine (anti-tumor immunity modulator) | • Promote cytotoxicity and IFN-γ production • Mediate CD4+ T helper cells transformation to Th1 phenotype, enhance cell based immunity • Up-regulate NKG2D related NKs anti-tumor immunity | |
IL-8 | Pro-inflammatory cytokine | • Trigger potent pro-inflammatory signals in HCC; promote HCC immune evasion and metastasis • Enhance HCC-related fibrosis and Tregs enrichment in tumor tissue | |
IL-10 | Inhibitory cytokine that involves in both innate and adaptive immunity in HCC | • Tolerogenic DCs/ FcγRIIlow/−B cells derived IL-10 induces hepatic tolerance by promoting T cell hypo-responsiveness • Suppress CD4+ T cells activity via CTLA-4-dependent manner • IL-10 production is associated with Foxp3+ Tregs accumulation in HCC • Accelerate HCC progression by mediating polarization of alternatively activated M2 macrophages | |
IL-6/STAT3 | Pro-inflammatory/carcinogenesis signaling | • Mediate MDSCs activation then result in immunosuppression • Up-regulate IL-10, IDO expression; down-regulate IFN-γ; induce T cells dysfunction and apoptosis | |
PD-1/PD-L1 | Immune checkpoint molecules | • Impairing anti-tumor immunity and promotes CD8+ T cells exhaustion and apoptosis • PD-1 over-expressed myeloid cells, such as DCs, suppress T cell responses in HCC | |
LAG3 | Immune checkpoint molecule | • Up-regulated on TAA-specific T cells • Significantly impairs CD4+ and CD8+ TILs functions in HCC | [112] |
CTLA-4 | Immune checkpoint molecule | • Mediates immunosuppression by inducing Tregs activity and IDO and IL-10 productions in DCs • Suppresses the proliferation of T cells | |
Tim3/Galectin-9 pathway | Immune checkpoint signaling | • Negatively regulates Th1-mediated immune responses • Mediates CTLs dysfunction and immunosuppressive responses in HBV-associated HCC • Fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages | |
VEGF, PDGF, HGF | Major growth factors in TME of HCC | • Enhance interactions between TAFs/HSCs and HCC cells • Mediates recruitment of immune inhibitory cells • Mediates other pro-inflammatory signals in TME (e.g. IL-6/STAT3 axis) • Promotes angiogenesis and immune evasion | |
IDO | Immunosuppressive modulator | • High level IDO expression is associated with poor prognosis and high recurrence rate in HCC patients; a potential target for HCC immunotherapy • Enhance regulation of immune responses, such as T-cell proliferation impairment, promotion of Tregs expansion • IDO derived from HSCs and CAFs impair cytotoxicity and cytokine production of NK cells • CD14+CTLA-4+ regulatory DCs derived IDO suppress CTLs response; cause NKs dysfunction in HCC anti-tumor immunity | |
SDF-1α/CXCR4 | A multiple signaling that mediates HCC immune evasion, progression and metastasis | • Enhance interactions between TAFs/HSCs and HCC cells • Facilitate MDSCs recruitment and generation, then results in immune evasion • Contribute to HCC fibrosis and hypoxia • Synergize with other stroma-derived cytokines (such as HGF, VEGF, TGF-β and so on), promoting HCC growth, angiogenesis, metastasis | [116] |
CXCL17 | 119-amino acid chemokine | • An independent factor that correlates with HCC regulatory immune cells infiltration • Predict poor prognosis of HCC | [70] |
CCL2(also named MCP-1) | Multifunctional factor | • Multiple cellular resources, including HSCs, hepatocytes, macrophages and so on • CCL2/CCR2 promotes regulatory cytokines release, M2-macrophages accumulation and polarization • Suppress cytotoxic CD8+ T lymphocytes anti-tumor responses • Facilitate TANs infiltration in HCC | [118] |
Hypoxia (HIF-1α) | Versatile modulator of TME and tumor immunotolerant state | • Promote recruitment of Treg, MDSCs. • regulate release of multiple chemokines and inflammatory factors; Activate transcription of C-C motif ligand 26, 28 (CCL26, CCL28) and interleukines (ILs). • contribute to immune tolerance and angiogenesis. | |
CXCL1/CXCR2 signaling | Immunosuppressive signaling axis | • Impair immune balance in TME of HCC. • Facilitate immune escape via increasing MDSCs recruitment and repressing infiltration of IFNγ+CD8+ T cells. | [121] |
CXCL5 | C-X-C motif chemokine | • Recruits more TANs infiltration and contributes to TANs-induced HCC immune evasion. | [55] |
CCL15 | Immunosuppressive signaling | • Serves as an independent factor for HCC prognosis and survival. • Recruit CCR1 + CD14+ monocytes infiltration, accelerate tumor proliferation and metastasis by activating STAT1/erk1/2 signaling. • Upregulate immune checkpoints (e.g. PD-L1, Tim3) and immune tolerogenic enzymes (e.g. IDO, ARG) | [122] |
Current immunotherapeutic strategies for HCC
Immune checkpoint inhibitors
Programmed cell death protein-1 and its ligand (PD-1, PD-L1)
Regimen | Disease | Mechanism of action | Estimated/Actual enrollment | NCT number |
---|---|---|---|---|
Anti-CTLA-4 antibody based monotherapy/combination therapy | ||||
Tremelimumab+TACE | Liver cancer | Anti-CTLA-4 antibody; chemoembolization | 61 | NCT01853618 |
Tremelimumab | Advanced HCC | Anti-CTLA-4 antibody | 20 | NCT01008358 |
Ipilimumab +Nivolumab/ Nivolumab alone following SBRT | Unresectable HCC | Anti-PD-1 antibody, anti-CTLA-4 antibody | 50 | NCT03203304 |
Anti-PD-1 antibody based monotherapy/combination therapy | ||||
Nivolumab+Y90 Radioembolization | HCC | Liver-localized radioembolization, PD-1 blockade | 40 | NCT03033446 |
Nivolumab+cabozantinib | Advanced HCC | Neoadjuvant therapy, PD-1 blockade | 15 | NCT03299946 |
Nivolumab+Pexa Vec | HCC | Oncolytic Immunotherapy, PD-1 blockade | 30 | NCT03071094 |
Nivolumab+Ipilimumab | HCC (Resectable and potentially resectable) | CTLA-4 blocade, PD-1 blockade | 45 | NCT03222076 |
Nivolumab following selective internal radiation therapy (SIRT) | HCC (unresectable) | PD-1 blockade, radiation therapy | 40 | NCT03380130 |
Nivolumab following complete resection | HCC | PD-1 blockade | 530 | NCT03383458 |
Nivolumab+Galunisertib | NSCLC HCC | TGF-β receptor I kinase inhibitor, PD-1 blockade | 75 | NCT02423343 |
Nivolumab+Lenvatinib | HCC | TKI + PD-1 blockade | 26 | NCT03418922 |
Nivolumab+Y90 | HCC | PD-1 blockade+Radioembolization | 35 | NCT02837029 |
Nivolumab+Sorafenib | HCC | PD-1 blockade+chemotherapy | 40 | NCT03439891 |
Nivolumab+CC-122 (Avadomide) | HCC (unresectable) | PD-1 blockade+immunomodulator (targeting protein cereblon) | 50 | NCT02859324 |
Nivolumab+deb-TACE | Advanced HCC | PD-1 blockade+transarterial chemoembolization | 14 | NCT03143270 |
Nivolumab+Mogamulizumab | HCC other solid tumors | PD-1 blockade+anti-CCR4 antibody | 188 | NCT02705105 |
TATE followed by Nivolumab or Pembrolizumab | HCC; mCRC | PD-1 blockade+TACE | 40 | NCT03259867 |
Nivolumab | Advanced HCC (with or without viral infections) | PD-1 blockade | 262 | NCT01658878 |
Nivolumab (vs. Sorafenib) | Advanced HCC | PD-1 blockade | 726 | NCT02576509 |
Anti-PD-L1 antibody based monotherapy/combined therapy | ||||
Durvalumab+tremelimumab | Unresectable HCC | Anti-PD-L1 antibody, anti-CTLA-4 antibody | 440 | NCT02519348 |
Durvalumab monotherapy; Durvalumab+Tremelimumab vs. Sorafenib | Unresectable HCC | Anti-PD-L1 antibody, anti-CTLA-4 antibody | 1200 | NCT03298451 |
Durvalumab+Guadecitabine (SGI-110) | Liver cancer; pancreatic cancer; bile duct cancer; gallbladder cancer | Anti-PD-L1 antibody, small molecule DNA methyltransferase 1 (DNMT1) inhibitor | 90 | NCT03257761 |
Durvalumab+Tremelimumab+ablative therapies | Advanced HCC and BTC | Anti-PD-L1 antibody, anti-CTLA-4 antibody | 90 | NCT02821754 |
Durvalumab+Ramucirumab (LY3009806) | GEJ adenocarcinoma; NSCLC; HCC | Anti-PD-L1 antibody, anti-VEGFR2 antibody | 114 | NCT02572687 |
Anti-LAG-3 antibody in combination with anti-PD-1 blockade | ||||
Relatlimab+Nivolumab | Different types of solid tumor (including HCC) | Anti-LAG-3 antibody,anti-PD-1 antibody | 1000 | NCT01968109 |
Cytotoxic T lymphocyte protein 4 (CTLA-4)
Mucin domain-containing molecule-3 (Tim-3) and lymphocyte activation gene 3 protein (LAG-3)
Adoptive cell transfer (ACT) based therapy in HCC
Regimen | Population | Design | Estimated/Actual enrollment | NCT number |
---|---|---|---|---|
CIKs mono-therapy for HCC | ||||
CIKs | • Hepatocellular carcinoma | • Phase 3 clinical trial • CIK treatments within 3 months after liver resection | 200 | NCT00769106 |
CIKs | • Hepatocellular carcinoma • Renal cell carcinoma • Lung cancer | • Phase 1 clinical trial • CIK treatments following radical resection | 40 | NCT01914263 |
CIKs | • Hepatocellular carcinoma | • Phase 3 clinical trial • CIK treatments following radical resection | 200 | NCT01749865 |
DC-CIKs | • Hepatocellular carcinoma | • Phase 2 clinical trial • Dendritic and CIKs used to treat HCC patients who got CR or PR after complete resection/ TACE | 100 | NCT01821482 |
CIKs in combination with other therapies for HCC | ||||
CIKs+ anti PD-1 antibodies | • Hepatocellular carcinoma • Renal cell carcinoma • Bladder cancer • Colorectal cancer • Non-small-cell lung cancer • Breast cancer | • Phase 2 clinical trial • Combination therapy | 50 | NCT02886897 |
CIKs+ TACE | • Hepatocellular carcinoma • Digestive system neoplasms | • Phase 3 clinical trial • Combination therapy | 60 | NCT02487017 |
CIKs+ RFA | • Hepatocellular carcinoma | • Phase 3 clinical trial • RFA + Highly-purified CTL vs. RFA Alone for Recurrent HCC after partial hepatectomy | 210 | NCT02678013 |
CAR-T trials for HCC treatment | ||||
Anti-GPC3 CAR-T | • Hepatocellular carcinoma (GPC3 + advanced HCC) | • Phase 1/2 clinical trial | 20 | NCT03084380 |
Anti-GPC3 CAR-T | • Hepatocellular carcinoma (GPC3 + advanced HCC) | • Phase 1/2 clinical trial | 60 | NCT02723942 |
Autologous anti-AFP (ET1402L1)-CAR-T | • AFP expressing hepatocellular carcinoma | • Phase 1 clinical trial • The second generation CAR-T treatment | 18 | NCT03349255 |
Anti-GPC3 CAR-T | • Advanced hepatocellular carcinoma | • Phase 1 clinical trial | 13 | NCT02395250 |
Anti-GPC3 CAR-T | • Advanced hepatocellular carcinoma | • Phase 1 clinical trial | 30 | NCT03198546 |
TAI-GPC3-CAR-T | • Hepatocellular carcinoma | • Phase 1/2 clinical trial • GPC3-CAR-Ttreatment mediated by the method of transcatheter arterial infusion (TAI) | 30 | NCT02715362 |
Anti-GPC3 CAR-T | • Advanced hepatocellular carcinoma | • Phase 1/2 clinical trial • GPC3-CAR-Ttreatment by intratumor injection | 10 | NCT03130712 |
Anti-Mucin1 (MUC1) CAR-T | • Hepatocellular carcinoma • Non-small cell lung cancer • Pancreatic carcinoma • Triple-negative invasive breast carcinoma | • Phase 1/2 clinical trial • Patients with MUC1+ advanced refractory solid tumor | 20 | NCT02587689 |
Anti-GPC3 CAR-T | • Relapsed or refractory hepatocellular carcinoma | • A single arm, open-label pilot study • GPC3+ hepatocellular carcinoma | 20 | NCT03146234 |
Anti-EpCAM CAR-T | • Colon cancer • Esophageal carcinoma • Pancreatic cancer • Prostate cancer • Gastric cancer • Hepatic carcinoma | • Phase 1/2 clinical trial • Targeting patients with EpCAM+ cancer | 60 | NCT03013712 |
CAR-T targeting TAAs | • Hepatocellular carcinoma • Pancreatic cancer • Colorectal cancer | • Phase 1/2 clinical trial • CAR-T targets: GPC3 for hepatocellular carcinoma • Mesothelin for pancreatic cancer • CEA for colorectal cancer | 20 | NCT02959151 |
Non-cell based vaccines and oncolytic viruses based immunotherapy in HCC
Trial (the 1st author/ responsible party) | Agent | Design | Population | Status/Relevant results | Registration no.& Reference order |
---|---|---|---|---|---|
Non-cell based vaccines | |||||
Greten et al. (2010) | GV1001: a telomerase derived peptide vaccine | • A phase 2 open-label trial; 4-week injections with GM-CSF + GV1001 vaccinations • P:tumor response • S:TTP, TTSP, PFS, OS, safety and immune responses | 40 patients with advanced HCC | Status: terminated Results: no relevant toxicity, median OS: 11.5 months, median PFS: 57 days, median TTP: 57 days, TTSP: 11.7 months | [155] NCT00444782 |
Sawada et al. (2012) | GPC-3-derived peptide vaccine | • A phase 1 Trial • P: safety • S:TTP, OS, immune responses (measured by IFN-γ ELISPOT assay) | 33 patients with advanced HCC | Status: terminated Results: well-tolerated, 91% patients were successfully induced with CTLs-mediated responses, median OS: 9.0 months, median TTP: 3.4 months, GPC-3-specific CTL frequency after vaccination correlated with OS | [156] UMIN-CTR000001395 |
Butterfield et al. (2003) | AFP peptide vaccine | • A pilot Phase 1 clinical trial • In vivo studies testing AFP peptide- vaccine reactive T cells responses | 6 patients with HCC | Status: terminated Results: all of the patients generated T-cell responses to most or all of the peptides as measured by direct IFN –γ ELISPOT and MHC class I tetramer assays | [157] |
Immunitor LLC et al. (2018) | An oral therapeutic vaccine: hepcortespenlisimut-L (Hepko-V5) | • A phase 3, randomized, placebo-controlled, double-blinded trial • P:changes in serum AFP levels, tumor burden, OS | Estimated enrollment:120 patients with advanced HCC | Status: recruiting Results: none | NCT02232490 |
Roswell Park Cancer Institute (2016) | Vaccine therapy in treating NY-ESO-1 expressing solid tumors | • A phase 1 clinical trial determines the safety of DC205-NY-ESO-1 vaccine | 18 patients with NY-ESO-1 solid tumors, including HCC | Status: completed Results: none | NCT01522820 |
Butterfield et al. (2013) | AFP+ GM-CSF Plasmid Prime and AFP Adenoviral vector Boost | • A phase 1/2 trial • Testing immunization with AFP + GM CSF plasmid prime and AFP adenoviral vector | Actual enrollment: 2 patients with HCC | Status: terminated (Poor accrual and limited target patient population for future accrual, did not complete the Phase 1 portion of the trial.) | NCT00669136 |
Oncolytic virus (OVs) based immunotherapy | |||||
Byeong et al. (2008) | JX-594 | • A phase 1 clinical trial, assessment of intratumoral injection of JX-594 into primary or metastatic liver tumours • P:safety, MTD | 14 patients with primary or metastatic liver tumors | Status: terminated Results: well-tolerated; MTD was determined as 1 × 109 pfu; 10 patients were radiographically evaluable for objective responses; responses in 3 HCC patients: 3 serum tumor markers PR (≥50% decrease); 1 response according to PET | [158] (NCT00629759) |
Jeong Heo et al. (2013) | JX-594 | • A Prospective, randomized clinical trial with high or low dose JX-594 • P: intrahepatic disease control rate | 30 patients with unresectable liver tumors | Status: terminated Results: 11/16 patients showed cytotoxicity against HCC; 31% anorexia in high dose group RR: 4 PR, 10 SD by RECIST | [159] (NCT00554372) |
Jennerex Biotherapeutics (2008–2011) | JX-594 (Pexa-Vec) | • A phase 2b randomized trial • JX-594 plus best supportive care versus best supportive care in patients with advanced HCC who have failed Sorafenib treatment | 129 patients with advanced HCC who have failed sorafenib | Status: completed Results: none (No results posted on ClinicalTrials.gov) | NCT01387555 |
SillaJen, Inc. (2015) | Vaccinia virus based immunotherapy (Pexa-Vec) + Sorafenib | • A multi-center, randomized, open-label, Phase 3 trial; • Comparing Vaccinia Virus based Immunotherapy Plus Sorafenib vs Sorafenib alone | 600 patients with advanced HCC | Status: recruiting Results: none | NCT02562755 |